Long-Term Survival in Patients with Metastatic Melanoma who Received Ipilimumab in Four Phase II Trials — ASN Events
  1. Schedule
  2. Posters - Clinical research
  3. Long-Term Survival in Patients with Metastatic Melanoma who Received Ipilimumab in Four Phase II Trials

Long-Term Survival in Patients with Metastatic Melanoma who Received Ipilimumab in Four Phase II Trials (#168)

Celeste Lebbe 1 , Jeffrey Weber 2 , Michele Maio 3 , Bart Neyns 4 , Kaan Harmankaya 5 , Omid Hamid 6 , Steven O'Day 7 , Kevin Chin 8 , Diane Opatt McDowell 9 , Lori Cykowski 8 , M B McHenry 8 , Jedd D Wolchok 10
  1. Saint-Louis Hospital, Paris, France
  2. Moffitt Cancer Center, Tampa, FL, United States
  3. University Hospital of Siena, Siena, Italy
  4. UZ Brussel, Brussels, Belgium
  5. Medical University of Vienna, Vienna, Austria
  6. The Angeles Clinic and Research Institute, Santa Monica, CA, USA
  7. Beverly Hills Cancer Center, Beverly Hills, CA, USA
  8. Bristol-Myers Squibb, Wallingford, CT, United States
  9. Bristol-Myers Squibb, Lawrenceville, NJ, United States
  10. Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Publish consent withheld